{
  "ticker": "JNJ",
  "target_date": "2025-11-07",
  "actual_date": "2025-11-07",
  "collected_at": "2025-12-08T12:30:23.533782",
  "price": {
    "open": 186.56,
    "high": 187.16,
    "low": 184.53,
    "close": 185.39291381835938,
    "volume": 6959200,
    "change_1d_pct": -0.21,
    "change_7d_pct": -0.02,
    "change_30d_pct": 3.82
  },
  "technicals": {
    "rsi_14": 29.35,
    "sma_20": 188.51,
    "sma_50": 183.13,
    "macd": 0.335,
    "macd_signal": 1.227,
    "macd_histogram": -0.892,
    "bb_upper": 193.75,
    "bb_lower": 183.26,
    "price_vs_sma20_pct": -1.65,
    "price_vs_sma50_pct": 1.24,
    "volume_ratio": 0.86
  },
  "fundamentals": {
    "market_cap": 487978139648,
    "pe_ratio": 19.550175,
    "forward_pe": 19.107527,
    "price_to_book": 6.147443,
    "price_to_sales": 5.2955337,
    "profit_margin": 27.26,
    "operating_margin": 30.2,
    "roe": 33.62,
    "roa": 8.26,
    "revenue_growth": 6.8,
    "earnings_growth": 91.0,
    "debt_to_equity": 57.766,
    "current_ratio": 1.074,
    "quick_ratio": 0.711,
    "dividend_yield": 258.0,
    "fifty_two_week_high": 207.81,
    "fifty_two_week_low": 140.68,
    "fifty_day_avg": 193.4922,
    "two_hundred_day_avg": 170.2741,
    "analyst_target": 203.41833,
    "analyst_recommendation": "buy",
    "num_analysts": 24,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -2.54,
    "pct_from_52w_low": 43.97
  },
  "macro": {
    "spy": {
      "price": 670.97,
      "change_1d_pct": 0.1,
      "change_7d_pct": -1.3
    },
    "vix": {
      "level": 19.08,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.09
    },
    "dollar_index": {
      "level": 99.6
    },
    "gold": {
      "price": 3999.4
    },
    "regime": "BEAR_NORMAL"
  },
  "news": [
    {
      "headline": "Will Recursion Pharmaceuticals\u2019 (RXRX) New CEO Accelerate Its AI Ambitions and Strategic Partnerships?",
      "source": "Yahoo",
      "datetime": 1762539149,
      "summary": "In recent days, Recursion Pharmaceuticals announced a major leadership transition appointing Najat Khan, Ph.D., as CEO effective January 1, 2026, while also securing a milestone payment from Roche and Genentech for delivering a whole-genome microglial immune cell map. This leadership change brings a",
      "url": "https://finnhub.io/api/news?id=a0ad5c654fc2e309c8019602f20c064a951baf723e84b9212092d5da757cbd42"
    },
    {
      "headline": "J&J\u2019s Darzalex gains first FDA approval in smouldering multiple myeloma",
      "source": "Yahoo",
      "datetime": 1762531213,
      "summary": "This approval marks a milestone for high-risk sMM patients, but analyst Biswajit Podder notes that there are caveats to its future success.",
      "url": "https://finnhub.io/api/news?id=bc50e90ba072c8c6c6b29660fcee82ee8dc62631e7cc14f11c1c53d0a38701f9"
    },
    {
      "headline": "Is a Market Correction Coming? Better Grab 5 of the Safest Dividend Kings Now",
      "source": "Yahoo",
      "datetime": 1762526939,
      "summary": "These five Dividend Kings offer investors a solid source of passive income, and are among the safest picks in the group.",
      "url": "https://finnhub.io/api/news?id=fc0fd82ca6de80fda5b5681ef2b5fe7c4c616aafd16680ecb95147ca35cd1433"
    },
    {
      "headline": "FDA Approved DARZALEX Faspro\u00ae for Adult Patients with High-Risk Smoldering Multiple Myeloma",
      "source": "Yahoo",
      "datetime": 1762522200,
      "summary": "Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Johnson & Johnson received U.S. Food and Drug Administration (FDA) approval of a new indication for DARZALEX Faspro\u00ae (daratumumab and hyaluronidase-fihj) co-formulated with ENHANZE\u00ae, as single agent treatment of adult patient",
      "url": "https://finnhub.io/api/news?id=36899c07fb8ecbc69e056423b97c2a265f4b98ce600026c200add0ae72972680"
    },
    {
      "headline": "Johnson & Johnson: Dividends Don't Lie",
      "source": "SeekingAlpha",
      "datetime": 1762494041,
      "summary": "Discover J&J\u00e2\u0080\u0099s latest dividend growth, Q3 earnings, and outlook. Learn what signals profit headwinds and where new innovations may offer future value.",
      "url": "https://finnhub.io/api/news?id=a611d327e99f3ed6c509e46442d5a2c1ed5b69a64b837574489b969cbb45c79b"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "10-Q",
      "date": "2025-10-22",
      "description": "jnj-20250928.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000209/jnj-20250928.htm"
    },
    {
      "form": "4",
      "date": "2025-10-20",
      "description": "xslF345X05/wk-form4_1761002033.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000204/xslF345X05/wk-form4_1761002033.xml"
    },
    {
      "form": "8-K",
      "date": "2025-10-14",
      "description": "jnj-20251014.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000201/jnj-20251014.htm"
    },
    {
      "form": "4",
      "date": "2025-09-11",
      "description": "xslF345X05/wk-form4_1757627547.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000196/xslF345X05/wk-form4_1757627547.xml"
    },
    {
      "form": "4",
      "date": "2025-09-11",
      "description": "xslF345X05/wk-form4_1757627315.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000194/xslF345X05/wk-form4_1757627315.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}